Aptose Biosciences (APTO) Tops Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Aptose Biosciences Reports Results for the Second Quarter Ended June 30, 2015
August 4, 2015 4:07 PM EDTSAN DIEGO AND TORONTO, Aug. 4, 2015 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO) (TSX: APS) ("Aptose" or the 'Company") a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today reported financial results for the three months ended June 30, 2015 and provided a corporate update. Unless specified otherwise, all amounts are in Canadian dollars.
Effective July 15, 2014 the Company changed its fiscal year end from May 31 to December 31. As a result of this change, the current interim period being reported is for the... More
